ClinicalTrials.Veeva

Menu

Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear

CooperVision logo

CooperVision

Status

Completed

Conditions

Myopia

Treatments

Device: fanfilcon A (test)
Device: enfilcon A (control)

Study type

Interventional

Funder types

Industry

Identifiers

NCT02555722
FC150625

Details and patient eligibility

About

This study is a masked, multi-center, daily wear, monthly replacement, bilateral, randomized, lens blocked (subjects remain in the same lens brand throughout the study) concurrent control study enrolling up to 90 subjects with a study duration of approximately three months. Subjects will be randomized into the study contact lenses in a two to one (2:1) ratio of fanfilcon A lens (test) to enfilcon A lens (control).

Full description

Subjects will be randomized into the study contact lenses in a two to one (2:1) ratio of fanfilcon A lens (test) to enfilcon A lens (control). This should result in a study population of approximately 60 test subjects and 30 control subjects.

Enrollment

92 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Be at least 18 years of age as of the date of evaluation for the study.

  • Have:

    • Read the Informed Consent
    • Been given an explanation of the Informed Consent
    • Indicated understanding of the Informed Consent
    • Signed the Informed Consent document.
  • Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.

  • Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.

  • Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.

  • Be in good general health, based on his/her knowledge.

  • Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.

  • Have manifest refraction Snellen visual acuities (VA) equal to or better than20/25 in each eye.

  • To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.

Exclusion criteria

  • Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. Note: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.

  • Poor personal hygiene.

  • Any active participation in another clinical trial during this trial or within 30 days prior to this study.

  • To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.

  • A member, relative or household member of the investigator or of the investigational office staff.

  • Has a known sensitivity to the ingredients used in the Multi-Purpose Disinfection Lens Care System (MPS) approved for use in the study and is unable or unwilling to use the alternate care system.

  • Previous refractive surgery; or current or previous orthokeratology treatment.

  • Is aphakic or pseudophakic.

  • Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.

  • The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.

  • The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.

  • A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.

  • A history of papillary conjunctivitis that has interfered with contact lens wear.

  • Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

    • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2
    • Pterygium
    • Corneal scars within the visual axis
    • Neovascularization or ghost vessels > 1.0 mm in from the limbus
    • Giant papillary conjunctivitis (GPC) of > Grade 2
    • Anterior uveitis or iritis
    • Seborrheic eczema, seborrheic conjunctivitis or blepharitis

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

92 participants in 2 patient groups

fanfilcon A (test)
Experimental group
Description:
Subjects will be randomized to wear fanfilcon A lens (test) for one month of daily wear during the study.
Treatment:
Device: fanfilcon A (test)
enfilcon A (control)
Active Comparator group
Description:
Subjects will be randomized to wear enfilcon A lens (control) for one month of daily wear during the study.
Treatment:
Device: enfilcon A (control)

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems